Aktis Oncology
AKTS
Aktis Oncology (AKTS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Initiated Coverage | Outperform | $35.00 | Aug 19, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $37.00 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $33.00 from $30.00 | Jul 14, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $40.00 | Jun 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 from $33.00 | Jun 2, 2026 |
| William Blair | Initiated Coverage | Outperform | — | Apr 29, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $33.00 from $30.00 | Mar 31, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $30.00 | Mar 9, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $30.00 | Feb 3, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $31.00 | Feb 3, 2026 |
Frequently asked questions
What is the latest analyst rating on AKTS?
On Aug 19, 2026, Wedbush initiated coverage of Aktis Oncology at Outperform with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.